More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Data ReadoutpositiveLeqembiPositive

AI Analysis

Summary

Eisai presented real-world LEADER study data showing that Leqembi-treated early Alzheimer's disease patients demonstrated high stability rates (>75%) with nearly 7% improvement over 17 months of treatment. The positive real-world evidence supports the clinical benefit profile of lecanemab in early AD patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Real-world LEADER study showed nearly 83% of early Alzheimer's disease patients treated with Leqembi remained stable or improved, with more than 75% remaining stable and nearly 7% improving over an average of 17 months

Importance:6/10

Sentiment:

0.75

Alzheimer's diseasereal-world dataclinical efficacyconference presentation

Related Companies

$BIOA-B.ST $ESALY

Read the original article

Published by PR Newswire Pharma on July 14, 2026 3:41 PM

Read Original